{"nctId":"NCT00577473","briefTitle":"Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)","startDateStruct":{"date":"2001-02"},"conditions":["Ulcerative Colitis"],"count":301,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: mesalamine"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: mesalamine"]}],"interventions":[{"name":"mesalamine","otherNames":[]},{"name":"mesalamine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* confirmed diagnosis of ulcerative colitis\n\nExclusion Criteria:\n\n* a history of allergy or hypersensitivity to salicylates or aminosalicylates;\n* a history of extensive small bowel resection","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Patients Classified as Treatment Success at Week 6, ITT Population","description":"Treatment Success - complete or partial response; Complete = complete resolution of clinical assessments (stool frequency, rectal bleeding, PFA \\[patient's functional assessment\\], sigmoidoscopy) and PGA (physician global assessment) = 0, Partial = improvement from baseline PGA score and improvement in at least 1 of the clinical assessments \\[decrease of at least 1 on scale\\] and no worsening \\[no score increases\\] of remaining clinical assessments. Each clinical assessment graded using scale 0/normal, better thru 3/severe, worse.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.3","spread":null},{"groupId":"OG001","value":"55.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Classified as Treatment Success at Week 3, ITT Population","description":"Treatment Success - complete or partial response; Complete = complete resolution of clinical assessments (stool frequency, rectal bleeding, PFA \\[patient's functional assessment\\], sigmoidoscopy) and PGA (physician global assessment) = 0, Partial = improvement from baseline PGA score and improvement in at least 1 of the clinical assessments \\[decrease of at least 1 on scale\\] and no worsening \\[no score increases\\] of remaining clinical assessments. Each clinical assessment graded using scale 0/normal, better thru 3/severe, worse.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.0","spread":null},{"groupId":"OG001","value":"38.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Physician's Global Assessment (PGA) Percentage of Patients Improved at Week 3, All Randomized Patients","description":"PGA - 0-quiescent disease activity (all 0's) , 1-mild (mostly 1's), 2-moderate (mostly 2's), 3-severe (mostly 3's) based upon on scoring for stool frequency, rectal bleeding, PFR (patient's functional assessment - 0-well, 1-fair, 2-poor, 3-terrible), sigmoidoscopy findings. Improvement defined as either complete response (remission, score = 0) or partial response (improvement on treatment). Scoring Scale: 0-good thru 3-worse.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.3","spread":null},{"groupId":"OG001","value":"44.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Physician's Global Assessment (PGA) Percentage of Patients Improved at Week 6, All Randomized Patients","description":"PGA - 0-quiescent disease activity (all 0's) , 1-mild (mostly 1's), 2-moderate (mostly 2's), 3-severe (mostly 3's) based upon on scoring for stool frequency, rectal bleeding, PFR (patient's functional assessment - 0-well, 1-fair, 2-poor, 3-terrible), sigmoidoscopy findings. Improvement defined as complete response (remission, score = 0) or partial response (improvement on treatment). Scoring Scale: 0-good thru 3-worse.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.4","spread":null},{"groupId":"OG001","value":"64.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Stool Frequency Improvement at Week 3, All Randomized Patients (Percentage)","description":"0: normal stool frequency per day, 1: 1-2 stools greater than normal per day, 2: 3-4 stools greater than normal per day, 3: 5 or more stools greater than normal per day, Scoring Scale: 0-good thru 3-worse.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.7","spread":null},{"groupId":"OG001","value":"54.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Stool Frequency Improvement at Week 6, All Randomized Patients (Percentage)","description":"0: normal stool frequency per day, 1: 1-2 stools greater than normal per day, 2: 3-4 stools greater than normal per day, 3: 5 or more stools greater than normal per day, Scoring Scale: 0-good thru 3-worse.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.2","spread":null},{"groupId":"OG001","value":"66.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Rectal Bleeding Improvement at Week 3, All Randomized Patients (Percentage)","description":"0: no blood seen, 1: streaks of blood with stool less than half of the time, 2: obvious blood with stool most of the time, 3: blood alone passed, Scoring Scale: 0-good thru 3-worse.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1","spread":null},{"groupId":"OG001","value":"59.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Rectal Bleeding Improvement at Week 6, All Randomized Patients (Percentage)","description":"0-no blood seen, 1- streaks of blood with stool less than half of the time, 2- obvious blood with stool most of the time, 3- blood alone passed. Scoring Scale: 0-good thru 3-worse.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.2","spread":null},{"groupId":"OG001","value":"71.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Improvement in Patient's Functional Assessment (PFA) at Week 3, All Randomized Patients (Percentage)","description":"0-generally well, 1-fair, 2-poor, 3-terrible","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.2","spread":null},{"groupId":"OG001","value":"49.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Improvement in Patient's Functional Assessment (PFA) at Week 6, All Randomized Patients (Percentage)","description":"0-generally well, 1-fair, 2-poor, 3-terrible","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.1","spread":null},{"groupId":"OG001","value":"60.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Improvement in Patient's Sigmoidoscopy Assessment Score at Week 3, All Randomized Patients (Percentage)","description":"0-normal (intact vascular pattern, no friability or granularity), 1-mild (erythema; diminished or absent vascular markings; mild granularity; friability), 2-moderate (marked erythema, granularity; absent vascular markings; bleeds with minimal trauma; no ulcerations), 3-severe (spontaneous bleeding, ulcerations). Scoring Scale: 0-good thru 3-worse.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.5","spread":null},{"groupId":"OG001","value":"52.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Improvement in Patient's Sigmoidoscopy Assessment Score at Week 6, All Randomized Patients (Percentage)","description":"0-normal (intact vascular pattern, no friability or granularity), 1-mild (erythema; diminished or absent vascular markings; mild granularity; friability), 2-moderate (marked erythema, granularity; absent vascular markings; bleeds with minimal trauma; no ulcerations), 3-severe (spontaneous bleeding, ulcerations). Scoring Scale: 0-good thru 3-worse.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"73.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":154},"commonTop":["Headache","Nausea","Abdominal Pain","Infection","Diarrhea"]}}}